Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).

• Koeberle, Dieter Claraspital, Basel, Switzerland
• Dufour, Jean-Francois Department of Clinical Pharmacology, University Bern, Berne, Switzerland
• Demeter, Gyula St. László Teaching Hospital, Budapest, Hungary
• Samaras, Panagiotis University Hospital Zurich, Zurich, Switzerland
• Saletti, Piercarlo Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
• Li, Qiyu SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland
• Roth, Arnaud University Hospital Geneva, Geneva, Switzerland
• Horber, Daniel Kantonsspital St. Gallen, St. Gallen, Switzerland
• Buehlmann, Michael University Hospital Bern, Berne, Switzerland
• Wagner, Anna Dorothea Multidisciplinary Oncology Center, Lausanne University Hospital, Lausanne, Switzerland
• Montemurro, Michael University Hospital Zurich, Zurich, Switzerland
• Lakatos, Gabor St. László Teaching Hospital, Budapest, Hungary
• Ribi, Karin International Breast Cancer Study Group, Bern, Switzerland
• Feilchenfeld, Jonas Hôpital du Valais, Sion, Switzerland
• Peck-Radosavljevic, Markus Department of Gastroenterology and Hepatology, Vienna General Hospital and Medical University, Vienna, Austria
• Rauch, Daniel Regionalspital Thun, Thun, Switzerland
• Cvijetic, Ivana SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland
• Tschanz, Britta SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland
• Bodoky, Gyorgy Szent László Hospital, Budapest, Hungary

Cancer Research

Oncology